
Check out Investor Copilot custom GPT, which lets you enjoy ChatGPT functionality with recent financial information
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
Conversationally interact with ChatGPT to now analyze updated prices, technical indicators, financial statements, macro-economic/company news & more for Stocks, ETFs & Cryptos
[ALNY] Alnylam Pharmaceuticals Inc - Shareholder Equity / Assets
Data updated 2023-Sep-23 (Saturday)Note: Detailed Statistics for Shareholder Equity / Assets in Balance Sheet for Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] with frequency distribution chart that analyze trends & history . Total Shareholder Equity / Total Assets is expressed as a %. View Balance Sheet for broader context
Share
Quarterly Shareholder Equity / Assets values for Alnylam Pharmaceuticals Inc are rounded to enhance readability
2023-Jun | 2023-Mar | 2022-Dec | 2022-Sep | 2022-Jun | 2022-Mar | |
---|---|---|---|---|---|---|
Shareholder Equity / Assets | -12.0% | -7.6% | -4.5% | -1.9% | 5.3% | 11.7% |
Sequential Quarter Growth | -56.9% | -71.3% | -132.3% | -136.3% | -54.7% | -27.6% |
Quarter-on Quarter Growth | -326.7% | -165.4% | -127.6% | -108.8% | -78.2% | -59.0% |
Annual Shareholder Equity / Assets values for Alnylam Pharmaceuticals Inc are rounded to enhance readability
2022-Dec | 2022-Jan | 2021-Jan | 2020-Jan | 2019-Jan | 2018-Jan | |
---|---|---|---|---|---|---|
Shareholder Equity / Assets | -4.5% | -4.5% | 16.1% | 29.8% | 60.1% | 82.7% |
Year-on-Year Growth | 0.0% | -127.6% | -45.9% | -50.4% | -27.3% | -6.6% |
2-yr CAGR | -48.2% | -39.9% | -17.6% | |||
3-yr CAGR | -42.0% | -30.4% | ||||
4-yr CAGR | -34.7% | |||||
5-yr CAGR |
Frequency distribution of quarterly Shareholder Equity / Assets values from 2016-Dec-31 grouped into buckets. Latest Shareholder Equity / Assets value is -12 as of 2023-Jun-30
Subsequent stock performance post earnings date till next announcement for Alnylam Pharmaceuticals Inc mapped with quarterly Shareholder Equity / Assets values reported at that time. Most recent value denoted with star
Select frequency and calculation type for Shareholder Equity / Assets above for vertical axis in scatter chart. Additionally choose type of performance for horizontal axis
Bayesian (Conditional Probability) analysis for Alnylam Pharmaceuticals Inc with subsequent post-earnings performance given Shareholder Equity / Assets values. Analysis uses quarterly data and subsequent relative performance benchmarked to S&P 500 index. Most recent quarter is denoted with a star and corresponding partial performance is excluded from calculations
Underperform (relative perf.) | Outperform (relative perf.) | |
---|---|---|
Shareholder Equity / Assets - Low | 56% | 44% |
Shareholder Equity / Assets - Medium | 33% | 67% |
Shareholder Equity / Assets - High | 63% | 38% |
Shareholder Equity / Assets (Sequential growth %) - Low | 44% | 56% |
Shareholder Equity / Assets (Sequential growth %) - Medium | 50% | 50% |
Shareholder Equity / Assets (Sequential growth %) - High | 63% | 38% |
Shareholder Equity / Assets (QoQ growth %) - Low | 63% | 38% |
Shareholder Equity / Assets (QoQ growth %) - Medium | 29% | 71% |
Shareholder Equity / Assets (QoQ growth %) - High | 71% | 29% |
Related to Alnylam Pharmaceuticals Inc
Information for Alnylam Pharmaceuticals Inc
Current Detail : Recent daily/monthly performance & benchmark comparison
Historical Detail : Historical performance & related information using Time Machine
Financial Statements : Analyze Income Statement, Balance Sheet & Cashflow Statement and also compare with peers Currently Viewing
Bayesian Statement Classifier : Investigate historical financial statements to make probabalistic predictions using Artificial Intelligence
Anomaly Detection : Investigate unusual recent performance & technicals with historical context using AI
Historical Seasonality : Seasonal performance by calendar months
Technical History : Popular Technical indicator trends (RSI, MACD etc.)
Metric Deciles : Contextualizing recent performance & technical levels into historical decile buckets
Dollar Cost Averaging : Dollar Cost Average (DCA) over time in your portfolio
Moving Averages : Key Simple & Exponential Moving Averages
Historical Analogues : Insights from closest historical matches to recent performance using Artificial Intelligence
Chart Pattern Matching : Insights from similar historical charts to recent chart using Artificial Intelligence
News Stories : News stories on 2025-Mar-11 on Google
SEC Reports : Quarterly reports around 2025-Mar-11 on SEC Edgar
Compare Alnylam Pharmaceuticals Inc with other assets
Market Performance : Recent performance across covered assets
Historical Performance : Prior & Subsequent performance across assets on a historical date
Market Technicals : Technical indicator levels across covered assets
Market Seasonality : Seasonal performance by calendar months across covered assets
Pair Correlations : Performance Correlations with other assets
Beta : Volatility relative to the broad market
Performance Comparison : Visually compare/benchmark performance with other assets over time
Side-by-Side Comparison : Contrast with other assets over time in a side-by-side presentation
Sector : Health Care sector performance which includes Alnylam Pharmaceuticals Inc
Industry : Biotechnology industry performance which includes Alnylam Pharmaceuticals Inc